Syndax Pharmaceuticals, Inc. · NASDAQ:SNDX
Syndax Pharmaceuticals — Q4 2021 Earnings Presentation
12 slides from Syndax Pharmaceuticals's earnings presentation, 2022
Slide 1: 4Q21 Earnings Presentation
Determined to realize a future in which people with cancer live longer and better than ever before 4Q21 EARNINGS PRESENTATION
Slide 2: Forward-looking statements disclosure
Forward-looking statements disclosure This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referenci
Slide 3: 2021: Transformative year for Syndax
2021: Transformative year for Syndax Initiated AGAVE-201 and AUGMENT-101 pivotal trials Signed global partnership with Incyte for axatilimab Presented robust data for SNDX-5613 & axatilimab at ASH Completed $86.5 M financing 3
Slide 4: High value growth through pipeline development and continued asset acquisition
High value growth through pipeline development and continued asset acquisition SNDX-5613: Axatilimab: Menin-MLL Pipeline expansion Anti–CSF-1R disruption Expand beyond R/R acute leukemia Expand into earlier lines of cGHVD • Expand pipeline through BD and fibrotic disease • Pivotal trials (AUGMENT) o
Slide 5: AUGMENT-101 registration trials underway in 3 distinct patient populations
AUGMENT-101 registration trials underway in 3 distinct patient populations Independent, pivotal trials 64 adults AUGMENT-101 AUGMENT-101-2A: MLLr ALL + up to 10 peds R/R MLLr or 64 adults AUGMENT-101-2B: MLLr AML mNPM1 + up to 10 peds acute leukemia 64 adults AUGMENT-101-2C: NPM1 mut AML + up to 10
Slide 6: Trials testing expanded opportunities for SNDX-5613 to initiate in 1H22
Trials testing expanded opportunities for SNDX-5613 to initiate in 1H22 BEAT-AML: AUGMENT-102: INTERCEPT: Frontline Ven/Aza combo R/R Chemo combo MRD-progression in AML Phase 1/3; Frontline Phase 1; Relapsed or refractory Phase 1; Beyond frontline mNPM1 or MLLr AML mNPM1 or MLLr AML/ALL mNPM1 or MLL
Slide 7: SNDX-5613: moving into frontline meaningfully expands market potential
SNDX-5613: moving into frontline meaningfully expands market potential with additional patients and increasing duration of Tx Potential best/first-in-class agent • Clear efficacy in refractory, advanced NPM1 and MLLr acute leukemia • High percentage of MRD negative responses Profile supports use in
Slide 8: AGAVE-201: ongoing global pivotal trial for axatilimab in chronic GVHD
: ongoing global pivotal trial for axatilimab in chronic GVHD Inclusion criteria: 0.3 mg/kg Q2W 70 patients Randomization • 6 years and older R/R 1:1:1 1 mg/kg Q2W 70 patients cGVHD • Recurrent or refractory 3 mg/kg Q4W 70 patients active cGVHD after at least 2 lines of systemic FPFV in Topline ther
Slide 9: 2022 and beyond: Partnership with Incyte enables expansion
Partnership with Incyte enables expansion into additional high value indications and new geographies Prevalence estimates ~215,000 US, ~335,000 WW2 Expansion into fibrotic indications: IPF Phase 2* >35,000 WW1 Expansion into EU, Japan, ROW ~14,000 US1 Expansion to 1st L cGHVD: JAK combo trial AGAVE-
Slide 10: Proven ability to build the pipeline
Proven ability to build the pipeline From UCB Business development continues to be a core strength of our business Axatilimab Clinical development leadership enables competitive advantage From Allergan/Vitae Established relationships enhance Menin-MLL identification and access to quality assets inhi
Slide 11: Financial highlights, 1Q 2022 and FY 2022 financial guidance
Financial highlights, 1Q 2022 and FY 2022 financial guidance Ticker SNDX (NASDAQ) Cash and short-term investments (as of December 31, 2021) $439.9 million Shares Outstanding* (as of December 31, 2021) 59.0 million 2022 Operating Expense Guidance Q1 2022 FY 2022 Research and Development $30-35 millio
Slide 12: Thank you. Questions?
Thank you. Questions? 12
Syndax Pharmaceuticals — Q4 2021 Earnings Presentation on 6ix